" class="no-js "lang="en-US"> ēlizur - Medtech Alert
Thursday, September 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ēlizur | Pharmtech Focus

ēlizur

About ēlizur

ēlizur

Founded in 1993, ēlizur has quickly grown into a musculoskeletal solutions industry leader. Our comprehensive packages, implemented by credentialed and licensed staff, improve patient outcomes with a personalized rehabilitation experience. Count on ēlizur to supply the most technologically advanced products, arrange convenient delivery, ensure proper fit, provide individualized training, and expertly process claims. All the while, offering exceptional customer service.

Related Story

Artificial Intelligence

 BioMech

BioMech, ēlizur Announce Partnership Integrating AI-enabled Motion Analytics into Physical Therapy Solution

June 23 2022

BioMech Health, a division of BioMech Holdings, LLC, and ēlizur, a leading musculoskeletal solutions provider, announced today a […]